CSTL Q4 2024 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q4 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$86M+30.5% YoY

Gross Profit

$70M81.3% margin

Operating Income

$4M4.7% margin

Net Income

$10M11.1% margin

EPS (Diluted)

$0.32

QoQ Revenue Growth

+0.6%

Cash Flow

Operating Cash Flow

$24M

Free Cash Flow

$17M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$531M

Total Liabilities

$75M

Stockholders' Equity

$456M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$66M	+30.5%
Gross Profit	$70M	$54M	+30.6%
Operating Income	$4M	-$6M	+171.6%
Net Income	$10M	-$3M	+471.7%

Revenue Segments

Dermatologic

$64M100%